C71T
CANCELLED SECTION 71
08/05/2026
Voltar para busca
Dado oficial do USPTO
VIROXIS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
02/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
17/03/2018
Data de registro
22/10/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/05/2026
Última transação
02/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
Paris, FR
Examinador
GOODWIN, KATRINA JOYE
Unidade examinadora
N40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
VIROXIS SAS
Representantes
Mari-Elise Paul McBrayer PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparations for the treatment of viral and infectious diseases and disordersincluding exogenous and endogenous virusesrejection of transplanted tissuesfeline immunodeficiency virusfeline leukemia virushuman T- lymphotropic virusHIV; chemical preparations for medical or pharmaceutical purposes for the treatment of viral and infectious diseases and disordersincluding exogenous and endogenous virusesrejection of transplanted tissuesfeline immunodeficiency virusfeline leukemia virushuman T-lymphotropic virusHIV
Classe 42
Evaluationsassessments and research in the fields of science and technology provided by engineers in the field of pharmaceutical preparations for use in the treatment of humans and animals; research and development for others in the field of pharmaceutical preparations for use in the treatment of humans and animals; technical project studies in the nature of scientific feasibility studies in the field of pharmaceutical preparations for use in the treatment of humans and animals
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
22/10/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
25/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/04/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
25/04/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/04/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/04/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/04/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
25/04/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
09/02/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/05/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/04/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
13/02/2020
FIMP
FINAL DISPOSITION PROCESSED
13/02/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/01/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
22/10/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/10/2019
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/10/2019
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
12/09/2019
CHPB
POST PUBLICATION AMENDMENT - ENTERED
27/08/2019
APET
ASSIGNED TO PETITION STAFF
23/08/2019
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
08/08/2019
CHPB
POST PUBLICATION AMENDMENT - ENTERED
21/05/2019
APET
ASSIGNED TO PETITION STAFF
15/05/2019
GPNX
NOTIFICATION PROCESSED BY IB
26/04/2019
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
15/04/2019
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
14/03/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/03/2019
PUBO
PUBLISHED FOR OPPOSITION
05/03/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/02/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
13/02/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/02/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/01/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/01/2019
ALIE
ASSIGNED TO LIE
16/01/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/01/2019
RFNT
REFUSAL PROCESSED BY IB
10/08/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
13/07/2018
RFRR
REFUSAL PROCESSED BY MPU
13/07/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/06/2018
CNRT
NON-FINAL ACTION WRITTEN
29/06/2018
DOCK
ASSIGNED TO EXAMINER
27/06/2018
MAFR
APPLICATION FILING RECEIPT MAILED
05/05/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/05/2018
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
30/04/2018
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
26/04/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VIROXIS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.